CN115611921A - 一种苯唑西林酸胺盐及相关晶型 - Google Patents
一种苯唑西林酸胺盐及相关晶型 Download PDFInfo
- Publication number
- CN115611921A CN115611921A CN202110791385.8A CN202110791385A CN115611921A CN 115611921 A CN115611921 A CN 115611921A CN 202110791385 A CN202110791385 A CN 202110791385A CN 115611921 A CN115611921 A CN 115611921A
- Authority
- CN
- China
- Prior art keywords
- oxacillin
- acid
- mezlocillin
- crystalline form
- diisopropylamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001019 oxacillin Drugs 0.000 title claims abstract description 35
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 title claims abstract description 34
- 239000002253 acid Substances 0.000 title claims abstract description 28
- -1 amine salt Chemical class 0.000 title claims abstract description 12
- 239000013078 crystal Substances 0.000 title abstract description 10
- 229960003994 oxacillin sodium Drugs 0.000 claims abstract description 18
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000012074 organic phase Substances 0.000 claims description 18
- 229940043279 diisopropylamine Drugs 0.000 claims description 12
- 238000002425 crystallisation Methods 0.000 claims description 10
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims description 10
- 229960000198 mezlocillin Drugs 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000012296 anti-solvent Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 5
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 claims description 4
- NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- LVAXIOBWWSTEKS-UHFFFAOYSA-L ethyl-[3-[4-[3-[ethyl(dimethyl)azaniumyl]propoxy]phenoxy]propyl]-dimethylazanium;diiodide Chemical compound [I-].[I-].CC[N+](C)(C)CCCOC1=CC=C(OCCC[N+](C)(C)CC)C=C1 LVAXIOBWWSTEKS-UHFFFAOYSA-L 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000012467 final product Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000005260 corrosion Methods 0.000 description 4
- 230000007797 corrosion Effects 0.000 description 4
- 238000004455 differential thermal analysis Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960000281 trometamol Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 101000935445 Staphylococcus aureus Beta-lactamase Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229940103185 mefenamate Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
- C07D499/76—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with hetero rings directly attached to the carboxamido radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/03—Monoamines
- C07C211/07—Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/03—Monoamines
- C07C211/08—Monoamines containing alkyl groups having a different number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/14—Preparation of salts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/18—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
本发明提供了一种稳定性良好的苯唑西林酸胺盐,基于该胺盐,本发明还提供了相关晶型及其制备方法,同时还提供了通过该苯唑西林酸胺盐制备苯唑西林钠的方法。
Description
技术领域
本发明涉及药物中间体、药物制备领域。
背景技术
苯唑西林钠,青霉素类抗生素,口服和肌内注射用于轻度感染,静脉注射或静脉滴注用于严重感染。主要用于抗葡萄球菌,具有耐金葡球菌β-内酰胺酶的能力。本品钠盐为白色结晶性粉末,无臭或微臭,味苦。可溶于水、乙醇,不溶于乙醚、丙酮,微溶于氯仿。
现目前对苯唑西林钠的制备过程中,多是采用苯唑西林酸与碱反应后生成苯唑西林钠的路径。苯唑西林酸的使用使得该路径方法存在如下主要问题:其一,苯唑西林酸稳定性不佳,容易导致后续产生大量的杂质,降低产率,后期纯化成本高。
由于苯唑西林酸的不稳定性,也导致该原料不便于贮存,市场上无法大量获取该原料,制造苯唑西林钠时仍然需要先进行制备出苯唑西林酸,导致终产品的生产工艺被迫延长。即便有原料出售,由于其不稳定性和腐蚀性,也会导致储存和运输成本过高,不利于降低终产品成本。
发明内容
基于上述问题,本发明拟提供一类稳定性良好的苯唑西林盐,同时还提供了通过该苯唑西林胺盐制备苯唑西林钠的方法。基于该胺盐的稳定性,为苯唑西林钠的制备提供更多便利。
具体地,本发明提供了一种苯唑西林盐,以期通过成盐来提升中间体的稳定性,实验发现,唑西林酸的二丙胺盐、二乙胺盐、三乙胺盐、二异丙胺盐、NN- 二异丙基乙胺盐具备一定的稳定性,其中尤其以二异丙胺盐稳定性最佳,主要杂质增量不明显,主成分保留率极高。
基于稳定性研究,本发明最终提供了一种苯唑西林铵盐,更进一步提供了二异丙胺盐,该盐可以固体形式稳定存在,将其作为苯唑西林钠的中间体,不仅可以改善苯唑西林酸不稳定而带来的杂质问题,同时,该中间体便于贮存和运输,更是提升了终产品苯唑西林钠的生产效率,降低了成本。
本发明还发现,苯唑西林二异丙胺盐可以晶型形式存在,本发明制备得到的其中一种晶型,采用CuKα射线,其X射线粉末衍射图谱中,至少在如下2θ角度有衍射峰:4.998、10.778、12.298、16.923、17.799、18.181、21.241、21.540、 22.060、23.980、25.720、26.839、30.298。
进一步地,其X射线粉末衍射图谱中,还在如下2θ角度有衍射峰:10.322、 11.541、13.601、14.119、15.263、20.459、20.919、22.800、24.140、27.120。
进一步地,所述晶型的TGA测定中,130℃开始分解;DSC测定中,在133.78℃和156.16℃处有吸热峰。
除了上述盐和晶型的稳定性优势以外,使用上述苯唑西林二异丙胺盐或晶型,还可以避免传统操作中苯唑西林酸对无菌管道、设备的腐蚀,从而提高生产安全性,避免生产过程中对耐腐蚀设备的特殊需求,提高生产便利性,降低生产成本。
除了上述几种铵盐外,还制备得到了苯唑西林赖氨酸或氨丁三醇盐,但发现它们不适合制备苯唑西林钠,主要原因包括:1)赖氨酸、氨丁三醇价格昂贵,且均为固体,回收困难;2)赖氨酸、氨丁三醇在结晶体系中溶解度较低,残留不易清除,对苯唑西林钠的质量影响很大;3)由于赖氨酸、氨丁三醇在结晶体系中溶解度低,易析出,导致苯唑西林钠析晶过快,有关物质和溶残不合格。
本发明中还提供了上述苯唑西林二异丙胺盐或晶型的制备方法,它包括如下内容:
苯唑西林酸、二异丙胺、有机溶剂A,有机相温度0~50℃反应,结晶,取固形物即得。
反应温度也可以是在0-10℃,10-20℃,20-30℃,30-40℃,40-50℃等等。
其中,所述有机溶剂A选自乙酸乙酯、乙酸异丙酯、醋酸丁酯、二氯甲烷。
结晶的方法可以使用有机合成中的常规方式,例如冷却、加入抗溶剂等等。
本发明在成盐反应后,可以加入或不加入抗溶剂。本发明所述抗溶剂,也称不良溶剂,即对目标化合物溶解性不佳的溶剂,若使用该溶剂,可以加快目标化合物固化或结晶。
本发明中所使用的抗溶剂可以选自环己烷、正庚烷、甲叔醚、异丙醚。
本发明中所述苯唑西林酸可以采用现有技术制备得到。
本发明中对于苯唑西林酸的制备,采用如下内容:
(1)3-苯基-5-甲基异恶唑-4-酰氯、6-APA、弱碱、有机溶剂B,反应温度0-50℃,优选20~30℃;
(2)反应液、乙酸乙酯,在酸性条件下分层,取有机相即为含有苯唑西林酸的溶液。
本发明还提供了一种苯唑西林钠的制备方法,先制备并分离得到本发明提供的铵盐固形物或者晶型,再制备苯唑西林钠。该方法是利用了苯唑西林胺盐或其晶型这一中间体的良好稳定性,使用该方法,可以将铵盐中间体的制备与终产物的制备工艺分开进行,不仅有利于对中间过程进行质量把控,同时也有利于终产品生产效率的提升。
使用本发明中间体,优势包括但不限于:
1、稳定性良好,有利于降低终产物有关物质含量,便于贮存运输,可以大幅提升终产物生产效率,降低成本。
2、结晶工艺可控,缓慢析晶,有利于有关物质、溶残、粒径等的控制,传统工艺由苯唑西林酸有机提取液制备,快速析晶,不利于质量控制。
3、无菌过滤时胺盐溶液为碱性体系,对无菌设备腐蚀性小,传统工艺无菌过滤料液为强酸性有机提取液,对无菌设备腐蚀风险高。
4、溶残明显低于传统工艺制备获得的苯唑西林钠。
附图说明
图1本发明苯唑西林酸二异丙胺盐XRD谱图
图2热重分析和差热分析图谱
具体实施方式
实施例1苯唑西林酸的制备
500mL三口瓶中,将11.27g 3-苯基-5-甲基异恶唑-4-酰氯溶于50mL丙酮的溶液,加入10g 6-APA溶于50mL2%NaHCO3溶液和50mL丙酮中溶液,室温搅拌 30min,加入100mL乙酸乙酯,用0.1M aqHCl调pH值至2-3,分层,有机相经水洗、饱和食盐水洗涤,无水硫酸钠干燥,过滤,即得含有苯唑西林酸的有机相。
实施例2苯唑西林酸的制备
500mL三口瓶中加入11.27g 3-苯基-5-甲基异恶唑-4-酰氯溶于50mL丙酮中的溶液,加入10g 6-APA溶于50mL2%NaHCO3溶液和50mL丙酮中,室温搅拌30min,加入200mL乙酸乙酯,用0.1M aqHCl调pH值至2-3,分层,有机相经水洗、饱和食盐水洗涤,无水硫酸钠干燥,过滤,即得含有苯唑西林酸的有机相。
实施例3
取实施例1制备的有机相,控制有机相温度20~30℃,向有机相中加入7g (1.5eq)二异丙胺,搅拌2.0~3.0h,后过滤获得21.6g苯唑西林酸二异丙胺盐,收率93.3%,纯度98.8%。
实施例4
取实施例2制备的有机相,控制有机相温度20~30℃,向有机相中加入7g (1.5eq)二异丙胺,搅拌2.0~3.0h,加入200mL环己烷,搅拌0.5~1.0h后过滤获得22g苯唑西林酸二异丙胺盐,收率95%,纯度98.5%。
实施例5
参照实施例3、4的方法,向有机相中加入二丙胺,制备得到苯唑西林酸二丙胺盐。
实施例6
参照实施例3、4的方法,向有机相中加入二乙胺,制备得到苯唑西林酸二乙胺盐。
实施例7
参照实施例3、4的方法,向有机相中加入三乙胺,制备得到苯唑西林酸三乙胺盐。
实施例8
参照实施例3、4的方法,向有机相中加入N,N-二异丙基乙胺,制备得到苯唑西林酸N,N-二异丙基乙胺盐。
本发明将上述实施例制备得到苯唑西林钠二异丙胺盐与其他盐,置于敞口器皿中,在60℃减压干燥箱中进行稳定性考察,结果如下:
表1不同盐在60℃温度下有关物质变化情况
本发明对实施例制备的苯唑西林酸二异丙胺盐进行如下检测:
P-XRD检测:
实验设备:DX-2700BH
实验条件:
辐射源:CuKα射线,40kV,30mA
测量方式:步进
步进宽度/采集时间:0.02°10.5s
角度范围:3-40°
实验过程:将固体粉末样品约0.1-0.2g,置于盲孔板中;载玻片压平制好样品;将已制备好的样品插于P-XRD测样台上,设定好储存位置,按上述实验条件测试P-XRD图谱。所得图谱如图1所示,其部分衍射峰数据如下表:
表2
热重分析、差热分析:
热重分析和差热分析图谱参见图2。
热重分析结果显示样品自室温至110℃保持恒重,表明样品不含有残留溶剂,自130℃左右开始样品失重明显,表明样品开始分解。差热分析显示样品在 133.78℃(Onset值)和156.16℃(Onset值)处有两个吸热峰,峰值为147.78℃和164.96℃,为溶解和掉盐峰,紧接着出现一放热峰,为分解放热峰。
本发明苯唑西林酸二异丙胺盐的稳定性考察:
使用药用低密度聚乙烯袋作为内包装,聚酯/铝/聚乙烯药品包装用复合膜袋作为外包装,将样品在5℃±3℃、25℃±2℃/60%RH±5%RH、30℃±2℃ /65%RH±5%RH的条件下进行稳定性考察,分别于0天、7天、15天、30天、60 天、90天取样检查本品有关物质质量,检测结果如下所示:
表3
根据上述结果可知,本发明提供的苯唑西林酸二异丙胺盐,具体良好的稳定性。
Claims (10)
1.一种苯唑西林酸胺盐,其特征在于:所述胺盐为下列其中之一:
苯唑西林酸二异丙胺盐、苯唑西林酸二丙胺盐、苯唑西林酸二乙胺盐、苯唑西林酸三乙胺盐、苯唑西林酸N,N-二异丙基乙胺盐,优选为苯唑西林酸二异丙胺盐。
2.一种苯唑西林二异丙胺盐晶型,其特征在于:其X射线粉末衍射图谱中,至少在如下2θ角度有衍射峰:4.998、10.778、12.298、16.923、17.799、18.181、21.241、21.540、22.060、23.980、25.720、26.839、30.298。
3.根据权利要求2所述的晶型,其特征在于:其X射线粉末衍射图谱中,还在如下2θ角度有衍射峰:10.322、11.541、13.601、14.119、15.263、20.459、20.919、22.800、24.140、27.120。
4.根据权利要求2或3所述的晶型,其特征在于:所述X射线粉末衍射图谱如图1所示。
5.根据权利要求2所述的晶型,其特征在于:所述晶型的TGA测定中,130℃开始分解;DSC测定中,在133.78℃和156.16℃处有吸热峰。
6.权利要求2-5的制备方法,其特征在于:它包括如下内容:
苯唑西林酸、二异丙胺、有机溶剂A,有机相温度0-50℃反应,结晶,取固形物即得。
7.根据权利要求6所述的制备方法,其特征在于:所述有机溶剂A选自乙酸乙酯、乙酸异丙酯、醋酸丁酯、二氯甲烷。
8.根据权利要求6所述的制备方法,其特征在于:反应后加入或不加入抗溶剂;进一步地,所述抗溶剂选自环己烷、正庚烷、甲叔醚、异丙醚。
9.根据权利要求6所述的制备方法,其特征在于:所述苯唑西林酸的制备方法包括如下内容:
(1)3-苯基-5-甲基异恶唑-4-酰氯、6-APA、弱碱、有机溶剂B,反应温度0-50℃,优选20~30℃;
(2)反应液、乙酸乙酯,在酸性条件下分层,取有机相即为含有苯唑西林酸的溶液。
10.一种苯唑西林钠的制备方法,其特征在于:先制备并分离得到权利要求1所述的胺盐固形物或者权利要求2-5所述的晶型,再制备苯唑西林钠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110791385.8A CN115611921B (zh) | 2021-07-13 | 2021-07-13 | 一种苯唑西林酸胺盐及相关晶型 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110791385.8A CN115611921B (zh) | 2021-07-13 | 2021-07-13 | 一种苯唑西林酸胺盐及相关晶型 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115611921A true CN115611921A (zh) | 2023-01-17 |
CN115611921B CN115611921B (zh) | 2024-04-09 |
Family
ID=84855801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110791385.8A Active CN115611921B (zh) | 2021-07-13 | 2021-07-13 | 一种苯唑西林酸胺盐及相关晶型 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115611921B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101003539A (zh) * | 2007-01-16 | 2007-07-25 | 广东中科药物研究有限公司 | 西林类化合物的氨丁三醇盐及其制备方法 |
CN101007810A (zh) * | 2007-01-24 | 2007-08-01 | 陈文展 | 西林类化合物的有机胺盐及其制备方法 |
CN102161668A (zh) * | 2011-05-05 | 2011-08-24 | 苏州二叶制药有限公司 | 苯唑西林钠及注射用苯唑西林钠的制备方法 |
-
2021
- 2021-07-13 CN CN202110791385.8A patent/CN115611921B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101003539A (zh) * | 2007-01-16 | 2007-07-25 | 广东中科药物研究有限公司 | 西林类化合物的氨丁三醇盐及其制备方法 |
CN101007810A (zh) * | 2007-01-24 | 2007-08-01 | 陈文展 | 西林类化合物的有机胺盐及其制备方法 |
CN102161668A (zh) * | 2011-05-05 | 2011-08-24 | 苏州二叶制药有限公司 | 苯唑西林钠及注射用苯唑西林钠的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115611921B (zh) | 2024-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6022985A (en) | Process for the preparation of 4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β-10β-trihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-tert-b utoxy-carbonYlamino-2-hydroxy-3-phenylpropionate trihydrate | |
TWI711626B (zh) | 達格列淨新穎特別晶型及其製備方法 | |
CZ54495A3 (en) | Process for preparing and/or purification of clavulanic acid | |
US10793532B2 (en) | Method for producing the crystalline form of modification a of calcobutrol | |
CN113149992B (zh) | 一种盐酸咪达唑仑f晶型的制备方法及用途 | |
CN112679498B (zh) | 磺酸季铵盐化合物及其制备方法和用途 | |
CN112645912B (zh) | 一种高纯度m2晶型麦考酚钠的制备方法 | |
WO2014097306A1 (en) | Stable and pure polymorphic form of bortezomib | |
CN115611921A (zh) | 一种苯唑西林酸胺盐及相关晶型 | |
CN116120393A (zh) | 一种氧化型谷胱甘肽及其晶型和杂质的制备方法 | |
US20090118496A1 (en) | Crystallization Method for Intermediates of Carbapenem Antibiotics | |
EP2977372B1 (en) | Polymorphs of febuxostat | |
CN109689620B (zh) | 拆分巴氯芬盐的方法 | |
JP4104166B2 (ja) | アモキシシリンの結晶塩の製造法 | |
CN115109248B (zh) | 四臂聚乙二醇戊二酸琥珀酰亚胺酯及其制备方法 | |
EP2690097B1 (en) | Method for crystallizing glutamic acid benzyl ester n-carboxylic anhydride | |
US20020137926A1 (en) | Process for preparing crystalline salts of amoxycillin | |
TWI768595B (zh) | 用於製備超純曲前列環素之高效結晶方法及由其製得之晶體 | |
CN116987025B (zh) | 一种氯解磷定的晶型及其制备方法 | |
CN117285428A (zh) | 一种盐酸多巴胺b晶型及其制备方法和应用 | |
EP3584247B1 (en) | Method for preparing canagliflozin amorphous form | |
RU2786716C2 (ru) | Способ получения кристаллической формы модификации a калкобутрола | |
CN107043405B (zh) | 多环杂环化合物的晶型、其制备方法、应用及组合物 | |
CN116444385A (zh) | 一种重酒石酸间羟胺的晶体、制备方法及应用 | |
CN106957311B (zh) | 雷替曲塞的溶剂化物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |